POM-V Prescription Required Companion Animal

Lozenord 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

Accord Healthcare B.V

VMD MA No.

42153/3000

What it's used for

Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats: Alleviation of mild to moderate post-operative pain...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Lozenord 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Reduction of post-operative pain and inflammation following orthopaedic and soft tissue
surgery.
Cats:
Alleviation of mild to moderate post-operative pain and inflammation following surgical
procedures in cats, e.g. orthopaedic and soft tissue surgery.

Cats: Subcutaneous use.
Dogs:
Musculo-skeletal disorders:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4
ml/10 kg body weight). A suitable oral meloxicam formulation, e.g. suspension or tablet,
administered in accordance with label recommendations, may be used for continuation of
treatment 24 hours after administration of the injection.
Reduction of post-operative pain (over a period of 24 hours):
Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body
weight (i.e.
0.4 ml/10 kg body weight) before surgery, for example at the time of induction of
anaesthesia.
Cats:
Reduction of post-operative pain and inflammation when administration of meloxicam is to
be continued as an oral follow-up therapy:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.04
ml/kg body weight) before surgery, for example at the time of induction of anaesthesia. A
suitable oral meloxicam formulation administered in accordance with label
recommendations, may be used for continuation of treatment 24 hours after administration
of the injection.
Reduction of post-operative pain and inflammation where no oral follow-up treatment is
possible e.g. feral cats:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06
ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.
In this case do not use oral follow up treatment.
The rubber stopper should not be punctured more than 24 times.
Particular care should be taken with regard to the accuracy of dosing. To ensure a correct
dosage, body weight should be determined as accurately as possible. The use of suitably
calibrated measuring equipment is recommended.
Avoid introduction of contamination during use.

Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Dogs and Cats
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports)
Appetite loss
, Lethargy
Vomiting
, diarrhoea
, blood in
faeces
1,2
, haemorrhagic diarrhoea
,
haematemesis
, gastric ulcer
, small
intestine ulcer
Elevated liver enzymes
Renal failure
Anaphylactoid reaction
1 These adverse events occur generally within the first treatment week and are in most
cases transient and disappear following termination of the treatment but in very rare
cases may be serious or fatal.
2 Occult
3 Should be treated symptomatically
If adverse reactions occur, treatment should be discontinued, and the advice of a
veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary
medicinal product. Reports should be sent, preferably via a veterinarian, to either the
marketing authorisation holder or the national competent authority via the national reporting
system. See the package leaflet for respective contact details.

None

Special precautions for safe use in the target species:
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential
risk of renal toxicity. During anaesthesia, monitoring and fluid therapy should be considered
as standard practice.
For post-operative pain and inflammation following surgical procedures in cats:
In case additional pain relief is required, multimodal pain therapy should be considered.

Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental self-injection may give rise to pain. People with known hypersensitivity to non-
steroidal anti- inflammatory drugs (NSAIDs) should avoid contact with the veterinary
medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the package
leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes, immediately rinse
thoroughly with water.
Special precautions for the protection of the environment:
Not applicable.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with
high protein binding may compete for binding and thus lead to toxic effects. Meloxicam may
also antagonise the antihypertensive effects of ACE inhibitors. The veterinary medicinal
product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at
anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during
anaesthesia should be taken into consideration. When anaesthesia and NSAID are
concomitantly administered, a risk for renal function cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such veterinary medicinal
products should be observed for at least 24 hours before commencement of treatment. The
treatment-free period, however, should take into account the pharmacological properties of
the products used previously.

Keep the vial in outer carton in order to protect from light.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.